Regulatory Approval
Alembic Receives USFDA Tentative Approval for Larotrectinib Capsules; Potential First-to-File Opportunity in U.S.
NSE
aplltd
BSE
533573
Alembic Pharmaceuticals Limited has received tentative approval from the USFDA for its ANDA for Larotrectinib Capsules (25 mg and 100 mg), the generic equivalent of Bayer’s Vitrakvi®. The company is the sole first applicant with a Paragraph IV certification and may qualify for 180 days of generic exclusivity upon final approval, creating a significant future commercial opportunity in the U.S. oncology market.
PRICE-SENSITIVE TRIGGER
Event: USFDA Tentative Approval for Larotrectinib Capsules, 25 mg and 100 mg.
Type: Regulatory Approval
Impact: Positive
Immediate Effect: The approval advances Alembic’s oncology pipeline in the U.S. market and positions the company for potential first-to-market generic commercialization upon receipt of final approval.
Key Metrics:
- U.S. Market Size (IQVIA, MAT March 2026): US$91 million
- ANDA Status: Tentative Approval
- Alembic Total USFDA ANDA Approvals: 241
- Final Approvals: 221
- Tentative Approvals: 20
Highlight:
- Potential 180-Day Exclusivity Opportunity: Alembic is the sole first applicant for the product under Paragraph IV certification and may be eligible for 180 days of generic marketing exclusivity in the U.S. following final approval.
What Happened ?
Alembic Pharmaceuticals announced that it has received tentative approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules in strengths of 25 mg and 100 mg.
The product is therapeutically equivalent to Bayer Healthcare Pharmaceuticals’ reference listed drug, Vitrakvi®. Larotrectinib is indicated for adult and pediatric patients with NTRK gene fusion-positive solid tumors where no satisfactory alternative treatments exist or where disease progression has occurred following treatment.
According to the latest Paragraph IV database update, Alembic is currently the sole first applicant for the product, strengthening its competitive position in the market.
Key Details
USFDA Oncology Product Approval:
- Tentative approval received for Larotrectinib Capsules, 25 mg and 100 mg.
- Product is the generic equivalent of Bayer’s Vitrakvi®.
- Larotrectinib is a kinase inhibitor used in treatment of NTRK gene fusion-positive solid tumors.
- The drug is approved for both adult and pediatric patients meeting specified treatment criteria.
- Alembic has filed the product under Paragraph IV certification provisions of the Hatch-Waxman Act.
- The company is currently the sole first applicant listed for this product.
- Final approval could qualify Alembic for 180 days of generic marketing exclusivity in the U.S.
- The product addresses a specialty oncology segment with a meaningful commercial opportunity.
Note:
- Tentative approval indicates regulatory acceptance of the application but commercialization can commence only after receipt of final approval and satisfaction of applicable patent or exclusivity requirements.
Risk Analysis
Summary:
- Commercial benefits depend on final USFDA approval timing, patent-related developments, and successful market entry execution.
Key Risks:
- Tentative approval does not permit immediate commercialization.
- Final approval remains subject to regulatory and legal requirements.
- Potential exclusivity benefits may depend on Paragraph IV outcomes and patent litigation developments.
- Oncology products typically face competitive pricing pressure after market entry.
- Revenue realization depends on successful launch execution and physician adoption.
Worst Case Scenario:
- Delays in final approval or adverse patent-related developments could postpone commercialization and reduce the expected exclusivity advantage.
Risk Level: Medium
Company Commentary
- Alembic has received tentative approval from the USFDA for Larotrectinib Capsules 25 mg and 100 mg.
- The company is the sole first applicant for the product under Paragraph IV certification.
- Upon final approval, Alembic may be eligible for 180 days of generic marketing exclusivity in the U.S.
- The approval strengthens Alembic’s oncology and specialty generics portfolio.
- Alembic’s cumulative USFDA ANDA approvals now stand at 241, including 221 final approvals and 20 tentative approvals.
Official Exchange Filing: Alembic Pharmaceuticals Limited